Hans Olav Høivik

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Thomas R. Pieber, Bruce W. Bode, Young Min Cho et al. · The Lancet Diabetes & Endocrinology · 2019 · 274 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Six months supplementation with conjugated linoleic acid induces regional-specific fat mass decreases in overweight and obese

Jean‐Michel Gaullier, Johan Halse, Hans Olav Høivik et al. · British Journal Of Nutrition · 2007 · 183 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +17

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +10

Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache

Hans Olav Høivik, Bart Laurijssens, Lutz Harnisch et al. · Cephalalgia · 2010 · 90 citations

Medicine, Pharmacology, Pharmacotherapy +16